Company Overview of Galena Biopharma, Inc.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company’s lead product candidate comprise NeuVax (nelipepimut-S), which is in Phase III clinical trials for use in the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human ...
4640 SW Macadam Avenue
Portland, OR 97239
Founded in 2003
Key Executives for Galena Biopharma, Inc.
Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Total Annual Compensation: $707.1K
Chief Financial Officer and Vice President
Total Annual Compensation: $299.4K
Total Annual Compensation: $145.5K
Compensation as of Fiscal Year 2014.
Galena Biopharma, Inc. Key Developments
Galena Biopharma, Inc. Announces Executive Changes
Jun 24 15
On June 24, 2015, Galena Biopharma, Inc. entered into a separation and consulting agreement with Margaret Kivinski pursuant to which her employment as Vice President and General Counsel was terminated on June 18, 2015 and under which she agrees to consult with the company regarding the legal aspects of business and operations for a six-month period commencing on June 18, 2015 and ending on December 18, 2015, unless the separation and consulting agreement is sooner terminated as provided therein. On June 24,2015, Thomas J. Knapp accepted employment offer letter to serve as interim General Counsel for the six-month period commencing on June 25, 2015 and ending on December 31, 2015. Until recently, Mr. Knapp served as the Executive Vice President, Chief Legal Officer and Corporate Secretary of Sucampo Pharmaceuticals, Inc. He will continue to serve as a consultant to Sucampo Pharmaceuticals, Inc. through August 2015.
Galena Biopharma, Inc. Approves Amendment to Amended and Restated Certificate of Incorporation
Jun 24 15
Galena Biopharma, Inc. announced that at the annual meeting held on June 19, 2015 approved an amendment to amended and restated certificate of incorporation to increase the number of shares of common stock authorized for issuance by 75,000,000 shares, to a total of 275,000,000 shares.
Galena Biopharma, Inc. Presents Phase 2 Clinical Trial of Gale-401 at the European Hematology Association 20th Congress in Vienna, Austria
Jun 15 15
Galena Biopharma, Inc. announced that data from the Company's Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs). The primary objective of the study was to estimate ORR with the secondary objectives of safety, tolerability and
pharmacokinetics (PK). Enrolled patients were adult men and women diagnosed with an MPN-related elevated platelet count to include chronic myelogenous leukemia (CML), polycythemia vera (PV), primary myelofibrosis (PMF), or ET.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|